| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883453 | The Annals of Thoracic Surgery | 2006 | 9 Pages |
Abstract
In this retrospective, subgroup analysis, pexelizumab reduced postoperative morbidity and myocardial injury in patients with multiple risk factors who underwent prolonged cross-clamp time during coronary artery bypass surgery. The clinical benefit of pexelizumab may be related to the effect of complement inhibition in the presence of potential ischemic-reperfusion injury associated with prolonged aortic cross-clamp time.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Peter K. MD, Michel MD, John C. MD, Axel MD, Jerrold H. MD, Philippe MD, Stanton K. MD, Frans MD, PhD, Peter X. MD, Thomas G. MD, Edward MD,